Issues
-
Cover Image
Cover Image
Prostaglandin E2, a bioactive lipid targeted by aspirin and COX-2.selective inhibitors, has previously been shown to promote cancer progression. Prostaglandin dehydrogenase(PGDH) catalyzes the rate-limiting step of Prostaglandin E2 catabolism in vivo Here we show Pgdh expression by in situ hybridization of ApcMin intestine, a mouse model of polyp formation. Pgdh is strongly expressed in normal tissue and much reduced in preinvasive adenomatous polyps, demarcated by a dotted line. This data supports a novel,COX-2.independent mechanism for accumulation of Prostaglandin E2 in colorectal cancer. For details, see the article by Mann et al. on page 6649 of this issue.
- PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Reviews
Priority Reports
Association of Mutant TP53 with Alternative Lengthening of Telomeres and Favorable Prognosis in Glioma
Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272
Molecular Biology, Pathobiology, and Genetics
RUNX3 Is Frequently Inactivated by Dual Mechanisms of Protein Mislocalization and Promoter Hypermethylation in Breast Cancer
Conditional Activation of RET/PTC3 and BRAFV600E in Thyroid Cells Is Associated with Gene Expression Profiles that Predict a Preferential Role of BRAF in Extracellular Matrix Remodeling
Cell, Tumor, and Stem Cell Biology
Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase–Positive Anaplastic Large Cell Lymphoma
Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma
Role of B-Cell–Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Sustained Expression of Early Growth Response Protein-1 Blocks Angiogenesis and Tumor Growth
Immunology
Clinical Research
Gene Expression Differences in Normal Esophageal Mucosa Associated with Regression and Progression of Mild and Moderate Squamous Dysplasia in a High-Risk Chinese Population
Epidemiology and Prevention
Disruption of Autophagy at the Maturation Step by the Carcinogen Lindane Is Associated with the Sustained Mitogen-Activated Protein Kinase/Extracellular Signal–Regulated Kinase Activity
TP53 and KRAS2 Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study
Neu-Induced Retroviral Rat Mammary Carcinogenesis: A Novel Chemoprevention Model for Both Hormonally Responsive and Nonresponsive Mammary Carcinomas
Letters to the Editor
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds